Abstract
Rationale
Synthetic cathinones have become increasingly available as drugs of abuse. Distribution of these drugs is made possible by altering the chemical structures of prohibited cathinones and marketing them under misleading labels. Very little is known about the relative reinforcing effectiveness of new synthetic cathinones relative to known drugs of abuse.
Objective
We examined self-administration of three second-generation synthetic cathinones: alpha-pyrrolidinopentiophenone (alpha-PVP), 4-methyl-N-ethylcathinone (4-MEC), and 4-methyl-alpha-pyrrolidinopropiophenone (4-MePPP) relative to methamphetamine.
Method
Male, Sprague-Dawley rats, implanted with intravenous catheters, were trained to self-administer methamphetamine (0.05 mg/kg/injection) under a fixed-ratio schedule. Following training, various doses of methamphetamine (0.006-0.1 mg/kg/injection), alpha-PVP (0.0015-0.1 mg/kg/injection), 4-MEC (0.1-3.2 mg/kg/injection), or 4-MePPP (0.1-0.8 mg/kg/injection) were available for self-administration in separate groups, followed by a behavioral-economics evaluation of the reinforcing effectiveness of each drug.
Results
For all drugs, at least one dose functioned as a reinforcer. Alpha-PVP and 4-MePPP maintained the highest numbers of infusions per session and both were more effective reinforcers relative to methamphetamine. 4-MEC and methamphetamine were not significantly different in terms of infusions per session or reinforcing effectiveness.
Conclusion
Emerging synthetic cathinones whose primary pharmacological mechanism is to block dopamine uptake but with little effects on monoamine release or serotonin uptake may have a greater degree of abuse potential compared with known abused stimulants.
Similar content being viewed by others
References
Aarde SM, Huang PK, Creehan KM, Dickerson TJ, Taffe MA (2013) The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats. Neuropharm 71:130–140. doi:10.1016/j.neuropharm.2013.04.003
Aarde SM, Creehan KM, Vandewater SA, Dickerson TJ, Taffe MA (2015) In vivo potency and efficacy of the novel cathinone α-pyrrolidinopentiophenone and 3, 4-methylenedioxypyrovalerone: self-administration and locomotor stimulation in male rats. Psychopharmacol 232:3045–3055. doi:10.1007/s00213-015-3944-8
Ator NA, Griffiths RR (2003) Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend 70:S55–S72. doi:10.1016/S0376-8716(03)00099-1
Baumann MH (2014) Awash in a sea of ‘bath salts’: implications for biomedical research and public health. Addict 109:1577–1579. doi:10.1111/add.12601
Bickel WK, DeGrandpre RJ, Higgins ST, Hughes JR (1990) Behavioral economics of drug self-administration. I. Functional equivalence of response requirement and drug dose. Life Sciences 47:1501–1510. doi:10.1016/0024-3205(90)90178-T
Drug Enforcement Administration, Department of Justice (2011a) Schedules of controlled substances: temporary placement of three synthetic cathinones into Schedule I. Final Order. Fed Regist 76:65371–65375
Drug Enforcement Administration, Department of Justice (2011b) Background, data and analysis of synthetic cathinones: Mephedrone (4-MMC), Methylone (MDMC) and 3,4-Methylenedioxypyrovalerone (MDPV). Office of Diversion Control, Drug and Chemical Evaulation Section, Washington, DC, pp. 1–29
Drug Enforcement Administration, Department of Justice (2013a) Establishment of drug codes for 26 substances. Final rule. Fed Regist 78:664–666
Drug Enforcement Administration, Department of Justice (2013b) Schedules of controlled substances: placement of Methylone into Schedule I. Final Order. Fed Regist 78:21818–21825
Drug Enforcement Administration, Department of Justice (2014a) Schedules of controlled substances: temporary placement of 10 synthetic cathinones into Schedule I. Final Order. Fed Regist 79:12938–12943
Drug Enforcement Administration, Department of Justice, National Forensic Laboratory Information System (2014b) Special report: Synthetic cannabinoids and synthetic cathinones reported in NFLIS, 2010-2013
Drug Enforcement Administration, Department of Justice (2016) Schedules of controlled substances: extension of temporary placement of 10 synthetic cathinones into Schedule I of the Controlled Substances Act. Final Order. Fed Regist 81:11429–11431
Gatch MB, Dolan SB, Forster MJ (2015a) Comparative behavioral pharmacology of three pyrrolidine-containing synthetic cathinone derivatives. J Pharmacol Exp Ther 354:103–110. doi:10.1124/jpet.115.223586
Gatch MB, Rutledge MA, Forster MJ (2015b) Discriminative and locomotor effects of five synthetic cathinones in rats and mice. Psychopharmacol 232:1197–1205. doi:10.1007/s00213-014-3755-3
Gunter BW, Jones SA, Paul IA, Platt DM, Rowlett JK (2016) Benzodiazepine and neuroactive steroid combinations in rats: anxiolytic-like and discriminative stimulus effects. Psychopharmacol. doi:10.1007/s00213-016-4369-8
Horton DB, Potter DM, Mead AN (2013) A translational pharmacology approach to understanding the predictive value of abuse potential assessments. Behav Pharmacol 24:410–436. doi:10.1097/FBP.0b013e3283644d2e
Hursh SR, Silberberg A (2008) Economic demand and essential value. Psychological Rev 115:186–198. doi:10.1037/0033-295X.115.1.186
Hursh SR, Winger G (1995) Normalized demand for drugs and other reinforcers. J Exp Anal Behav 64:373–384. doi:10.1901/jeab.1995.64-373
Huskinson SL, Naylor JE, Rowlett JK, Freeman KB (2014) Predicting abuse potential of stimulants and other dopaminergic drugs: overview and recommendations. Neuropharmacol 87:66–80. doi:10.1016/j.neuropharm.2014.03.009
Iversen L, White M, Treble R (2014) Designer psychostimulants: pharmacology and differences. Neuropharm 87:59–65. doi:10.1016/j.neuropharm.2014.01.015
Karila L, Megarbane B, Cottencin O, Lejoyeux M (2015) Synthetic cathinones: a new public health problem. Current Neuropharm 13:12–20. doi:10.2174/1570159X13666141210224137
Lile JA, Ross JT, Nader MA (2005) A comparison of the reinforcing efficacy of 3, 4-methylenedioxymethamphetamine (MDMA,“ecstasy”) with cocaine in rhesus monkeys. Drug Alcohol Depend 78:135–140. doi:10.1016/j.drugalcdep.2004.10.006
Marusich JA, Antonazzo KR, Wiley JL, Blough BE, Partilla JS, Baumann MH (2014) Pharmacology of novel synthetic stimulants structurally related to the “bath salts” constituent 3, 4-methylenedioxypyrovalerone (MDPV). Neuropharmacol 87:206–213. doi:10.1016/j.neuropharm.2014.02.016
Motbey CP, Clemens KJ, Apetz N, Winstock AR, Ramsey J, Li KM et al (2013) High levels of intravenous mephedrone (4-methylmethcathinone) self-administration in rats: neural consequences and comparison with methamphetamine. J Psychopharmacol 27:823–836. doi:10.1177/0269881113490325
Naylor JE, Freeman KB, Blough BE, Woolverton WL, Huskinson SL (2015) Discriminative-stimulus effects of second generation synthetic cathinones in methamphetamine-trained rats. Drug Alcohol Depend 149:280–284. doi:10.1016/j.drugalcdep.2015.02.002
Negus SS, Schrode K, Stevenson GW (2007) Mu/Kappa opioid interactions in rhesus monkeys: Implications for analgesia and abuse liability. Exp Clin Psychopharmacol 16:386–399. doi:10.1037/a0013088
Paillet-Loilier M, Cesbron A, Le Boisselier R, Bourgine J, Debruyne D (2014) Emerging drugs of abuse: current perspectives on substituted cathinones. Subst abuse rehabil 5:37–52. doi:10.2147/SAR.S37257
Saha K, Partilla JS, Lehner KR, Seddik A, Stockner T, Holy M, Sandtner W, Ecker GF, Sitte HH, Baumann MH (2015) ‘Second-generation’mephedrone analogs, 4-MEC and 4-MePPP, differentially affect monoamine transporter function. Neuropsychopharm 40:1321–1331. doi:10.1038/npp.2014.325
Simmler LD, Rickli A, Hoener MC, Liechti ME (2014) Monoamine transporter and receptor interaction profiles of a new series of designer cathinones. Neuropharm 79:152–160. doi:10.1016/j.neuropharm.2013.11.008
Smith DA, Negus SS, Poklis JL, Blough BE, Banks ML (2016) Cocaine-like discriminative stimulus effects of alpha-pyrrolidinovalerophenone, methcathinone and their 3, 4-methylenedioxy or 4-methyl analogs in rhesus monkeys. Addict Biol. doi:10.1111/adb.12399
Townsend EA, Beloate LN, Huskinson SL, Roma PG, Freeman KB (2015) Corn oil, but not cocaine, is a more effective reinforcer in obese than in lean Zucker rats. Physiol Behav 143:136–141. doi:10.1016/j.physbeh.2015.03.002
Wang Z, Woolverton WL (2007) Estimating the relative reinforcing strength of (±)-3, 4-methylenedioxymethamphetamine (MDMA) and its isomers in rhesus monkeys: comparison to (+)-methamphetamine. Psychopharmacol 189:483–488. doi:10.1007/s00213-006-0599-5
Watterson LR, Burrows BT, Hernandez RD, Moore KN, Grabenauer M, Marusich JA, Olive MF (2014a) Effects of α-pyrrolidinovalerophenone and 4-Methyl-N-ethylcathinone, two synthetic cathinones commonly found in second-generation “Bath Salts,” on intracranial self-stimulation thresholds in rats. I J Neuropsychopharmacol p.pyu014. doi:10.1093/ijnp/pyu014
Watterson LR, Kufahl PR, Nemirovsky NE, Sewalia K, Grabenauer M, Thomas BF et al (2014b) Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV). Addict Biol 19:165–174. doi:10.1111/j.1369-1600.2012.00474.x
Woolverton WL, Johanson CE (1984) Preference in rhesus monkeys given a choice between cocaine and d,l-cathinone. J Exp Anal Behav 41:35–43
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors have no conflicts of interest to disclose. This research was supported by the University of Mississippi Medical Center’s Drug Abuse Development Fund and the National Institute on Drug Abuse (NIDA) grant R01 DA12970 to B.E.B. Preparation of this manuscript was supported by the above mentioned funding sources in addition to NIDA grants F32 DA037619 to S.L.H., R01 DA033795 and R01 DA011792 to J.K.R., and R01 DA027666 and R01 DA039167 to K.B.F.
Rights and permissions
About this article
Cite this article
Huskinson, S., Naylor, J., Townsend, E. et al. Self-administration and behavioral economics of second-generation synthetic cathinones in male rats. Psychopharmacology 234, 589–598 (2017). https://doi.org/10.1007/s00213-016-4492-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-016-4492-6